1035 Adropin Measurements in Aneurysmal Subarachnoid Hemorrhage Patients and Postulated Protective Role

View at publisher Summarise with VIRAT
Authors: Zachary A. Sorrentino, Zahra Hasanpour Segherlou, Brandon Peter Lucke-Wold, William Dodd, Brian Lim Hoh, Matthew J. Koch, Nohra Chalouhi
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

INTRODUCTION: In aneurysmal subarachnoid hemorrhage (aSAH), cerebral vasospasm (CV) and subsequent delayed ischemia is a leading cause of morbidity. The brain peptide adropin decreases after SAH in animal models, and repletion of adropin protects against CV in them. Adropin has not been studied in aSAH patients. METHODS: In this prospective study, 24 patients with cerebral aneurysms were enrolled. Peripheral and intra-aneurysmal blood were collected during treatment, and patients requiring an external ventricular drain (EVD) had CSF collected. Adropin was measured via ELISA. RESULTS: Of 24 patients, 13 had aSAH, 9 developed CV, and 6 required EVDs. Average age was 56.3 ± 15.8 years, 84.2% were female, Hunt & Hess scale was 2.4 ± 0.8, modified Fisher scale 3.4 ± 0.6. 22 patients had serum + aneurysmal adropin collected, and 6 had serial CSF samples. Serum adropin was elevated compared to aneurysmal adropin in aSAH patients (6300 vs. 3900 pg/mL, p = 0.048) but not in unruptured patients (5800 vs. 3500 pg/mL, p = 0.12). Serum adropin did not differ from aneurysmal adropin in CV patients (5800 vs. 3800 pg/mL, p = 0.095) or non-CV patients (7300 vs. 4200 pg/mL, p = 0.21). CSF adropin decreased from bleed days 1-3 to days 4-6 (550 vs. 240 pg/mL, p = 0.023) and 13-15 (550 vs. 66 pg/mL, p = 0.003). CONCLUSIONS: Adropin significantly decreased in CSF after aSAH, and aneurysmal adropin was also decreased compared to peripheral blood in aSAH. Repletion of adropin in animal models of SAH was protective against development of CV, and similar augmentation in human aSAH patients may be beneficial in preventing CV.

Fields of Study & Subjects

Intracranial Aneurysms: Treatment and Complications Intracerebral and Subarachnoid Hemorrhage Research Takotsubo Cardiomyopathy and Associated Phenomena

Publication details

Journal / source
Neurosurgery
Volume
72
Issue
Supplement_1
Pages
184–184
Publication date
26 March 2026
Language
EN